Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence. / Grøndahl, V.; Binderup, T.; Langer, S. W.; Petersen, R. H.; Nielsen, K.; Kjaer, A.; Federspiel, B.; Knigge, U.

In: Lung Cancer, Vol. 132, 2019, p. 141-149.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Grøndahl, V, Binderup, T, Langer, SW, Petersen, RH, Nielsen, K, Kjaer, A, Federspiel, B & Knigge, U 2019, 'Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence', Lung Cancer, vol. 132, pp. 141-149. https://doi.org/10.1016/j.lungcan.2019.03.013, https://doi.org/10.1016/j.lungcan.2019.07.019

APA

Grøndahl, V., Binderup, T., Langer, S. W., Petersen, R. H., Nielsen, K., Kjaer, A., Federspiel, B., & Knigge, U. (2019). Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence. Lung Cancer, 132, 141-149. https://doi.org/10.1016/j.lungcan.2019.03.013, https://doi.org/10.1016/j.lungcan.2019.07.019

Vancouver

Grøndahl V, Binderup T, Langer SW, Petersen RH, Nielsen K, Kjaer A et al. Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence. Lung Cancer. 2019;132:141-149. https://doi.org/10.1016/j.lungcan.2019.03.013, https://doi.org/10.1016/j.lungcan.2019.07.019

Author

Grøndahl, V. ; Binderup, T. ; Langer, S. W. ; Petersen, R. H. ; Nielsen, K. ; Kjaer, A. ; Federspiel, B. ; Knigge, U. / Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence. In: Lung Cancer. 2019 ; Vol. 132. pp. 141-149.

Bibtex

@article{f3ba0d59891c414e9f63d539da91a79d,
title = "Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence",
abstract = "Background: Bronchopulmonary neuroendocrine tumours are divided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung cancer (SCLC). Aim: To thoroughly describe a cohort of 252 patients with TC, AC and LCNEC (SCLC excluded). Material and methods: Collection of data from 252 patients referred to and treated at Rigshospitalet 2008-2016. Data was collected from electronic patient files and our prospective NET database. Statistics were performed in SPSS. Results: 162 (64%)had TC, 29 (12%)had AC and 61 (24%)had LCNEC. Median age at diagnosis was 69 years (range: 19–89)with no difference between genders. Thoraco-abdominal CT was performed in all patients at diagnosis. FDG-PET/CT was performed in 207 (82%)at diagnosis and was positive in 95% of the entire cohort, with no difference between tumour types. Synaptophysin was positive in 98%, chromogranin A in 92% and CD56 in 97%. Mean Ki67 index was 5% in TC, 16% in AC and 69% in LCNEC (p < 0.001). Metastatic disease was found in 4% of TC, 27% of AC and 58% of LCNEC at time of initial diagnosis (p < 0.001). In total 179 patients (71%)underwent surgical resection; TC: 87%, AC: 72% and LCNEC: 28% (p < 0.001). Of the resected patients, 11 (6%)had recurrence. Five-year survival rate was 88% for TC, 63% for AC and 20% for LCNEC. Conclusion: In this comprehensive study of a cohort of 252 patients, one of the largest until date, with TC, AC and LCNEC, the gender distribution showed female predominance with 68%. FDG-PET/CT was positive in 95% of the patients independent of tumour type, which confirms that FDG-PET/CT should be a part of the preoperative work-up for TC, AC and LCNEC. Tumour type was the single most potent independent prognostic factor.",
keywords = "Atypical carcinoid, Bronchial neuroendocrine tumour, Bronchopulmonale tumour, Carcinoid tumour, FDG-PET, Ki67 index, Large cell neuroendocrine tumour, Mitotic count, Neuroendocrine neoplasm, Neuroendocrine tumour, Typical carcinoid",
author = "V. Gr{\o}ndahl and T. Binderup and Langer, {S. W.} and Petersen, {R. H.} and K. Nielsen and A. Kjaer and B. Federspiel and U. Knigge",
note = "Erratum: https://doi.org/10.1016/j.lungcan.2019.07.019",
year = "2019",
doi = "10.1016/j.lungcan.2019.03.013",
language = "English",
volume = "132",
pages = "141--149",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence

AU - Grøndahl, V.

AU - Binderup, T.

AU - Langer, S. W.

AU - Petersen, R. H.

AU - Nielsen, K.

AU - Kjaer, A.

AU - Federspiel, B.

AU - Knigge, U.

N1 - Erratum: https://doi.org/10.1016/j.lungcan.2019.07.019

PY - 2019

Y1 - 2019

N2 - Background: Bronchopulmonary neuroendocrine tumours are divided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung cancer (SCLC). Aim: To thoroughly describe a cohort of 252 patients with TC, AC and LCNEC (SCLC excluded). Material and methods: Collection of data from 252 patients referred to and treated at Rigshospitalet 2008-2016. Data was collected from electronic patient files and our prospective NET database. Statistics were performed in SPSS. Results: 162 (64%)had TC, 29 (12%)had AC and 61 (24%)had LCNEC. Median age at diagnosis was 69 years (range: 19–89)with no difference between genders. Thoraco-abdominal CT was performed in all patients at diagnosis. FDG-PET/CT was performed in 207 (82%)at diagnosis and was positive in 95% of the entire cohort, with no difference between tumour types. Synaptophysin was positive in 98%, chromogranin A in 92% and CD56 in 97%. Mean Ki67 index was 5% in TC, 16% in AC and 69% in LCNEC (p < 0.001). Metastatic disease was found in 4% of TC, 27% of AC and 58% of LCNEC at time of initial diagnosis (p < 0.001). In total 179 patients (71%)underwent surgical resection; TC: 87%, AC: 72% and LCNEC: 28% (p < 0.001). Of the resected patients, 11 (6%)had recurrence. Five-year survival rate was 88% for TC, 63% for AC and 20% for LCNEC. Conclusion: In this comprehensive study of a cohort of 252 patients, one of the largest until date, with TC, AC and LCNEC, the gender distribution showed female predominance with 68%. FDG-PET/CT was positive in 95% of the patients independent of tumour type, which confirms that FDG-PET/CT should be a part of the preoperative work-up for TC, AC and LCNEC. Tumour type was the single most potent independent prognostic factor.

AB - Background: Bronchopulmonary neuroendocrine tumours are divided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung cancer (SCLC). Aim: To thoroughly describe a cohort of 252 patients with TC, AC and LCNEC (SCLC excluded). Material and methods: Collection of data from 252 patients referred to and treated at Rigshospitalet 2008-2016. Data was collected from electronic patient files and our prospective NET database. Statistics were performed in SPSS. Results: 162 (64%)had TC, 29 (12%)had AC and 61 (24%)had LCNEC. Median age at diagnosis was 69 years (range: 19–89)with no difference between genders. Thoraco-abdominal CT was performed in all patients at diagnosis. FDG-PET/CT was performed in 207 (82%)at diagnosis and was positive in 95% of the entire cohort, with no difference between tumour types. Synaptophysin was positive in 98%, chromogranin A in 92% and CD56 in 97%. Mean Ki67 index was 5% in TC, 16% in AC and 69% in LCNEC (p < 0.001). Metastatic disease was found in 4% of TC, 27% of AC and 58% of LCNEC at time of initial diagnosis (p < 0.001). In total 179 patients (71%)underwent surgical resection; TC: 87%, AC: 72% and LCNEC: 28% (p < 0.001). Of the resected patients, 11 (6%)had recurrence. Five-year survival rate was 88% for TC, 63% for AC and 20% for LCNEC. Conclusion: In this comprehensive study of a cohort of 252 patients, one of the largest until date, with TC, AC and LCNEC, the gender distribution showed female predominance with 68%. FDG-PET/CT was positive in 95% of the patients independent of tumour type, which confirms that FDG-PET/CT should be a part of the preoperative work-up for TC, AC and LCNEC. Tumour type was the single most potent independent prognostic factor.

KW - Atypical carcinoid

KW - Bronchial neuroendocrine tumour

KW - Bronchopulmonale tumour

KW - Carcinoid tumour

KW - FDG-PET

KW - Ki67 index

KW - Large cell neuroendocrine tumour

KW - Mitotic count

KW - Neuroendocrine neoplasm

KW - Neuroendocrine tumour

KW - Typical carcinoid

UR - https://www.sciencedirect.com/science/article/pii/S0169500219305616?via%3Dihub

U2 - 10.1016/j.lungcan.2019.03.013

DO - 10.1016/j.lungcan.2019.03.013

M3 - Journal article

C2 - 31097087

AN - SCOPUS:85064623889

VL - 132

SP - 141

EP - 149

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -

ID: 226258599